During grower-finisher feed manufacturing, tiamulin hydrogen fumarate is incorporated into a medicated premix at a concentration that permits dilution to the final feed inclusion rate established in the regionally approved product dossier. The premix step is the primary technical bottleneck because the API particle size distribution, carrier porosity, and mixer shear profile determine whether the finished feed meets the ISO 6497:2002 sampling tolerance for active ingredient uniformity. A 1,000 kg twin-shaft paddle mixer loaded to 65–70% of gross volume is used for geometric dilution of the concentrated premix; the active is first blended with a compatible carrier such as calcium carbonate, lactose monohydrate, or wheat middlings screened below 500 µm. Carrier selection must account for the hygroscopicity of tiamulin hydrogen fumarate; moisture gain above a process-specific threshold causes bridging in screw conveyors and false readings in loss-in-weight feeders. The blended premix is transferred through a conical screener or hammermill for delumping before final mixing. At the pellet conditioner, retention time and temperature are critical because pleuromutilin derivatives are not infinitely heat tolerant. Conditioning at 75–85°C for 15–30 s is common for swine rations, but the formulator must validate potency recovery by Ph. Eur. 2.2.29 or USP <621> liquid chromatography on retained samples; published data for tiamulin hydrogen fumarate at conditioning temperatures above 85°C is limited. The final feed is assayed for tiamulin content and checked against the applicable MRL entries in Commission Regulation (EU) No 37/2010 Table 1 before release. The target pathogens in swine are Brachyspira hyodysenteriae, Brachyspira pilosicoli, Lawsonia intracellularis, Mycoplasma hyopneumoniae, and Actinobacillus pleuropneumoniae, but the API is not a universal growth promotor; inclusion in finishing diets must be justified by herd-level diagnostics. In production-scale batches, carryover into subsequent non-medicated feed is controlled by flushing the mixer, bucket elevator, and drag conveyor with a specified quantity of ground maize or wheat middlings; the flush material is then assayed to prevent cross-contamination above the permitted carryover limit defined in the feed safety program.

Why Does Injectable Tiamulin Demand an Acidic Vehicle and Sterility Validation?

Injectable formulations of tiamulin for pigs are prepared from the hydrogen fumarate salt because the free base has low aqueous solubility. The salt is dissolved in water for injection containing a co-solvent or buffer system; pH is maintained in the acidic range, typically below pH 4.5, to keep the active in solution and to minimise hydrolysis. The exact pH solubility profile must be established for the specific salt form and concentration because a fall below pH 3.0 may increase injection-site irritation while a rise above pH 5.0 may precipitate the active. The solution is filtered through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane prior to aseptic filling into Type II glass or multilayer plastic vials. Terminal steam sterilisation at 121°C for 15 min is used only if the manufacturer demonstrates that potency loss and related substances remain within the release limits described in the finished product dossier; otherwise, aseptic filtration is the default route. Release testing includes USP <85> bacterial endotoxins, Ph. Eur. 2.6.1 sterility, USP <905> uniformity of dosage units, and a stability-indicating assay by Ph. Eur. 2.2.29. The intramuscular route is used for acute swine dysentery outbreaks caused by Brachyspira hyodysenteriae and for respiratory disease complexes involving Mycoplasma hyopneumoniae and Pasteurella multocida, where feed or water medication is not practical. The injection volume, needle gauge, and site rotation are specified in the clinical protocol because repeated administration of acidic solutions can cause local muscle damage; the manufacturer must generate injection-site tolerance data under VICH GL43 or the applicable target-animal safety guidance. The withdrawal period is derived from the MRL entries in Commission Regulation (EU) No 37/2010 Table 1 and from residue depletion studies conducted under GLP; formulators cannot assume the same withdrawal period across different vehicles, species, or dose regimes.

In poultry integrations, soluble powder formulations of tiamulin hydrogen fumarate are metered into drinking water lines through proportional dosing pumps after reconstitution in a stock solution. The primary formulation constraint is not API solubility but the stability of the reconstituted stock solution in hard water; carbonate hardness above 200 mg/L CaCO₃ may alter the pH and shorten the use period, and published data for this specific configuration is limited. The powder is typically a spray-dried or wet-granulated blend of the active with dextrose, anhydrous citric acid, and a buffering agent; the fill weight is adjusted to deliver the approved mg/kg bodyweight dose when the stock solution is diluted at 0.1–1.0% into the main water line. Proportional dosing pumps require calibration before each flock cycle; failure to recalibrate after membrane replacement or water pressure fluctuation results in under-dosing or overdose. The medicated water is prepared fresh every 24 h unless the manufacturer has demonstrated longer chemical and microbiological stability. The target pathogens are Mycoplasma gallisepticum, Mycoplasma synoviae, and Clostridium perfringens, but regional labels differ in whether tiamulin is authorised for laying hens producing eggs for human consumption. In some jurisdictions, use in layers is restricted because egg residues are not covered by the MRL entry; the exporter must verify the current Commission Regulation (EU) No 37/2010 Table 1 entry and the destination country positive list before formulation. The powder is tested for loss on drying according to ISO 6496:1999 or Ph. Eur. 2.2.32, and for reconstitution clarity using a 25 µm filter test; any visible precipitate in hard water at the recommended dilution indicates a buffering failure rather than an active content failure.

When Granule Friability and Carrier Absorption Control Feed Top-Dressing Uniformity

Granulated tiamulin products for top-dressing or in-feed use are manufactured by wet granulation of the hydrogen fumarate salt with a binder solution sprayed onto a fluidised bed or high-shear granulator. The granule size distribution is the critical quality attribute because top-dressing onto pelleted feed requires adhesion to the pellet surface; granules below 125 µm segregate to the bottom of the feeder, while granules above 1.0 mm are not retained on the pellet and accumulate in the trough. Friability is measured under Ph. Eur. 2.9.7 or USP <1216> for tablet friability, but for feed granules a rotating drum or air-jet sieve method is more informative; the target is set to avoid dust generation during auger transfer and to maintain the declared active content after 30 min of mechanical agitation. The binder is typically povidone, hydroxypropyl methylcellulose, or pregelatinised starch, but the choice must avoid premature gelation in the high-shear bowl. Granulation liquid quantity is controlled by the binder viscosity and the carrier water absorption capacity; adding more than the carrier absorption threshold produces oversized agglomerates that block the final 1.0 mm screen. The dried granules are sieved, and the undersize fraction is either recycled or milled, depending on the residual moisture. The finished granules are blended with a flow agent such as colloidal silicon dioxide at 0.2–0.5 wt% to reduce interparticle cohesion. In field use, the granules are top-dressed at rates that depend on the approved dose and the feed intake of the target group; the mill must ensure that the active concentration is uniform from the first 50 kg to the last 50 kg of the batch by sampling according to ISO 6497:2002 and analysing by USP <621> or Ph. Eur. 2.2.29. The granulation route is preferred over simple powder blends when the API concentration is high and the premix will be stored in silos longer than 14 days because granules have lower surface area and slower moisture uptake.

Tablet and capsule presentations of tiamulin are not common in food-producing species because the dose per unit would require multiple units per animal and because withdrawal period management is more difficult than with feed or water medication. Published data for tiamulin hydrogen fumarate tablet and capsule formulations in non-food companion mammals is limited, and no broad pharmacopoeial monograph for such finished products exists. Where a developer prepares a tablet for a non-food species, the formulation would follow a standard direct compression or dry granulation route using lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The critical tests are USP <905> uniformity of dosage units, USP <711> dissolution, and Ph. Eur. 2.9.3 disintegration. Excipient compatibility must be examined because tiamulin hydrogen fumarate is acid-labile and can interact with basic lubricants such as magnesium stearate if the blend is overmixed. The low dose per tablet and the limited published safety data for chronic oral use in non-food species mean that any dossier must be supported by target animal safety studies rather than extrapolation from swine or poultry data. This segment is therefore a formulation-derived application rather than an established therapeutic field; downstream manufacturing complexity is low to moderate because standard solid-dose equipment is used, but the regulatory evidence base is thin.

Premix and Solution Use in Rabbit Enteropathy Requires Feed Palatability and Drinking Water Acidification Control

Rabbit enteropathy caused by susceptible anaerobic bacteria is treated with tiamulin via medicated feed or drinking water in jurisdictions where the species is listed in the MRL and product licence. The premix formulation used in rabbits is similar to the swine premix, but the feed matrix differs because rabbit rations contain higher fibre from alfalfa or soybean hulls and lower starch; this changes the adhesion and distribution of the API. The active is first diluted in a carrier with a particle size close to the fibre fraction, otherwise electrostatic charging separates the fine API from the larger fibre particles during mixing. Drinking water solutions for rabbits are acidified with citric acid to improve palatability and to stabilise the active, but acidification below pH 4.0 may reduce voluntary water intake in does and young rabbits. The dose is calculated on bodyweight and water intake; during heat stress, water intake rises and may lead to overconsumption if the solution is not adjusted. Release testing follows the same standards used for swine and poultry soluble powders, including Ph. Eur. 2.9.5 uniformity of mass for sachets and ISO 6496:1999 moisture for premix. The ionophore restriction also applies in rabbits: tiamulin must not be administered with monensin, narasin, or salinomycin because the combination can cause fatal toxicity. The formulator must confirm the current MRL entry in Commission Regulation (EU) No 37/2010 Table 1 for rabbit tissues because not all jurisdictions have identical marker residue definitions. The production line must be separated from ionophore-containing feeds and from non-target species feed to avoid carryover; the flush procedure is validated by detecting the active below the limit of quantitation of the HPLC method.

Ionophore Incompatibility During Feed Mill Production

The most serious process conflict in tiamulin feed manufacturing arises when the same feed mill handles ionophore anticoccidials including monensin, narasin, salinomycin, and lasalocid. Tiamulin is a selective inhibitor of CYP450-mediated metabolism in animals, and co-administration with ionophores can reduce the hepatic clearance of the ionophore to toxic levels. The interaction is not limited to simultaneous administration; residual ionophore carryover in a mixer, bucket elevator, or pelleting line can contaminate a tiamulin-containing batch and cause swine or rabbit mortality. A dedicated production line for tiamulin-containing feed is the most reliable control, but when shared equipment is unavoidable, the flush sequence must include the mixer, screw conveyor, elevator boot, pellet mill conditioner, and cooler; the flush volume is typically 300–500 kg of ground maize for a 1,000 kg mixer, but the exact volume is established by residue validation. The cleaning validation protocol uses the limit of quantitation of the USP <621> or Ph. Eur. 2.2.29 HPLC method for both tiamulin and the ionophore. The sequence of batches matters: tiamulin-containing feed should not follow an ionophore-containing feed without a full flush, and the flush material must be labelled as non-medicated but not automatically safe for all species if ionophore residues remain. Feed mills operating under hazard analysis critical control point programs document the flush and residue data in the batch release record. This incompatibility also affects the choice of carrier in premix manufacturing; carriers previously used for ionophore premixes must not be reworked into tiamulin premix unless analytically cleared.